Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2026 08:30 ET | Source: Vantive

Vantive Presents New Data at WCN on How Coordinated Care Ecosystems Can Expand Home-Based Peritoneal Dialysis Access and Improve Patient Outcomes

Nephroprotection and early intervention support more planned dialysis starts, improved patient outcomes and increased use of home therapies, according to new studies. Real-world studies also evaluate...
March 31, 2026 08:30 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus...
March 31, 2026 08:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain

First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a...
March 31, 2026 08:30 ET | Source: PolyPid Ltd.

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31,...
March 31, 2026 08:05 ET | Source: INNOVATE Corp.

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing...
March 31, 2026 08:00 ET | Source: Pheast Therapeutics

Pheast Therapeutics Advances PHST001, an IgG4 Anti-CD24 Monoclonal Antibody, into Phase 1b Combination Cohorts

First patient dosed in Phase 1b portion of ongoing Phase 1 study evaluating PHST001 in combination with chemotherapy Company to present three abstracts at AACR 2026, including preliminary clinical...
March 31, 2026 08:00 ET | Source: MediBeacon Inc.

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

ST. LOUIS, March 31, 2026 (GLOBE NEWSWIRE) -- MediBeacon Inc., a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today...
March 31, 2026 08:00 ET | Source: Anathapindika Health LLC

Anathapindika Shines Spotlight on Detoxification During National Nutrition Month

Fort Lauderdale, FL, March 31, 2026 (GLOBE NEWSWIRE) -- March is National Nutrition Month. As part of the ongoing focus on nutrition, Anathapindika is shining a spotlight on the growing awareness...
March 31, 2026 08:00 ET | Source: Adcytherix

Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth

Dosing of the first patient in the Phase 1 clinical trial of ADCX-020.
March 31, 2026 07:00 ET | Source: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of TNX-4800 demonstrated safety, tolerability, and...